Epilepsy and innate immune system: A possible immunogenic predisposition and related therapeutic implications

References

• Noe FM, Polascheck N, Frigerio F, Bankstahl M, Ravizza T, Marchini S, Beltrame L, Banderó CR, Löscher W, Vezzani A. Pharmacological blockade of IL-1β/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy. Neurobiol Dis 2013; 59:183-93; PMID:23938763; http://dx.doi.org/10.1016/j.nbd.2013.07.015
   PubMed Web of Science ®Google Scholar
• Vitaliti G. Pavone P. Mahmood F, Nunnari G, Falsaperla R. Targeting inflammation as a therapeutic strategy for drug-resistant epilepsies. An update of new immunomodulating approaches. Hum Vaccine Immunother 2014; 10:41-8; http://dx.doi.org/10.4161/hv.28400
   Google Scholar
• Falsaperla R, Pavone P, Miceli-Sopo S, Mahmood F, Scalia F, Corsello G, Lubrano R, Vitaliti G. Epileptic seizures as a manifestation of cow's milk allergy: a studied relationship and description of our pediatric experience. Expert Rev Clin Immunol 2014; 10:1597-609; PMID:25394911; http://dx.doi.org/10.1586/1744666X.2014.977259
   PubMed Web of Science ®Google Scholar
• Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr, Forsgren L, French JA, Glynn M, et al. ILAE Official Report: A practical clinical definition of epilepsy. Epilepsia 2014; 55:475-82; PMID:24730690; http://dx.doi.org/10.1111/epi.12550
   PubMed Web of Science ®Google Scholar
• de Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav 2008; 12:540-6; PMID:18280210
   PubMed Web of Science ®Google Scholar
• Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol 2003; 16:165-70
   PubMed Web of Science ®Google Scholar
• Banerjee PN, Filippi D, Allen Hauser W. The descriptive epidemiology of epilepsy—a review. Epilepsy Res 2009; 85:31-45; PMID:19369037; http://dx.doi.org/10.1016/j.eplepsyres.2009.03.003
   PubMed Web of Science ®Google Scholar
• Leonardi M, Ustun TB. The global burden of epilepsy. Epilepsia 2002; 43:21-5; PMID:12190974; http://dx.doi.org/10.1046/j.1528-1157.43.s.6.11.x
   PubMed Web of Science ®Google Scholar
• Sirven JI, Pedley TA, Wilterdink JL. Evaluation and management of drug-resistant epilepsy 2011.
   Google Scholar
• Lodish H, Berk A, Zipursky S. Molecular Cell Biology 4th edition 2000.
   Google Scholar
• Kumar H, Kawai T, Akira S. Pathogen recognition in the innate immune response. Biochem J 2009; 420:1-16; PMID:19382893; http://dx.doi.org/10.1042/BJ20090272
   PubMed Web of Science ®Google Scholar
• Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2011; 30:16-34; PMID:21235323; http://dx.doi.org/10.3109/08830185.2010.529976
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783-801; PMID:16497588; http://dx.doi.org/10.1016/j.cell.2006.02.015
   PubMed Web of Science ®Google Scholar
• Lemaitre B, Nicolas E, Michaut L, Reichhart J-M, Hoffmann JA. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996; 86:973-83; PMID:8808632; http://dx.doi.org/10.1016/S0092-8674(00)80172-5
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388:394-7; PMID:9237759; http://dx.doi.org/10.1038/41131
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, Modlin RL, Akira S. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002; 169:10-4; PMID:12077222; http://dx.doi.org/10.4049/jimmunol.169.1.10
   PubMed Web of Science ®Google Scholar
• Poltorak A, He X, Smirnova I, Liu M-Y, Van Huffel C, Du X, Modlin RL, Akira S. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282:2085-8; PMID:9851930; http://dx.doi.org/10.1126/science.282.5396.2085
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, Akira S. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999; 11:443-51; PMID:10549626; http://dx.doi.org/10.1016/S1074-7613(00)80119-3
   PubMed Web of Science ®Google Scholar
• Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410:1099-103; PMID:11323673; http://dx.doi.org/10.1038/35074106
   PubMed Web of Science ®Google Scholar
• Bowie AG, Haga IR. The role of Toll-like receptors in the host response to viruses. Mol Immunol 2005; 42:859-67; PMID:15829275; http://dx.doi.org/10.1016/j.molimm.2004.11.007
   PubMed Web of Science ®Google Scholar
• Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol 2004; 76:514-9; PMID:15178705; http://dx.doi.org/10.1189/jlb.0304127
   PubMed Web of Science ®Google Scholar
• Arancibia SA, Beltrán CJ, Aguirre IM, Silva P, Peralta AL, Malinarich F, Hermoso MA. Toll-like receptors are key participants in innate immune responses. Biol Res 2007; 40:97-112; PMID:18064347; http://dx.doi.org/10.4067/S0716-97602007000200001
   PubMed Web of Science ®Google Scholar
• Kang SS, Kauls LS, Gaspari AA. Toll-like receptors: applications to dermatologic disease. J Am Acad Dermatol 2006; 54:951-83; PMID:16713451; http://dx.doi.org/10.1016/j.jaad.2005.05.004
   PubMed Web of Science ®Google Scholar
• Akira S. Mammalian Toll-like receptors. Curr Opin Immunol 2003; 15:5-11; PMID:12495726; http://dx.doi.org/10.1016/S0952-7915(02)00013-4
   PubMed Web of Science ®Google Scholar
• Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003; 85:85-95; PMID:12527213; http://dx.doi.org/10.1016/S0165-2478(02)00228-6
   PubMed Web of Science ®Google Scholar
• Cai Z, Shi Z, Sanchez A, Zhang T, Liu M, Yang J, Wang F, Zhang D. Transcriptional regulation of Tlr11 gene expression in epithelial (16, 23, 83-85)
   Google Scholar
• Mallard C. Innate immune regulation by toll-like receptors in the brain. ISRN Neurol 2012; 2012:701950; PMID:23097717; http://dx.doi.org/10.5402/2012/701950
   PubMedGoogle Scholar
• Beg AA. Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol 2002; 23:509-12; PMID:12401394; http://dx.doi.org/10.1016/S1471-4906(02)02317-7
   PubMed Web of Science ®Google Scholar
• Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, Strauss JF 3rd. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001; 276:10229-33; PMID:11150311; http://dx.doi.org/10.1074/jbc.M100099200
   PubMed Web of Science ®Google Scholar
• Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001; 167:2887-94; PMID:11509636; http://dx.doi.org/10.4049/jimmunol.167.5.2887
   PubMed Web of Science ®Google Scholar
• Guillot L, Balloy V, McCormack FX, Golenbock DT, Chignard M, Si-Tahar M. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J Immunol 2002; 168:5989-92; PMID:12055204; http://dx.doi.org/10.4049/jimmunol.168.12.5989
   PubMed Web of Science ®Google Scholar
• Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, Miyake K, Freudenberg M, Galanos C, Simon JC. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002; 195:99-111; PMID:11781369; http://dx.doi.org/10.1084/jem.20001858
   PubMed Web of Science ®Google Scholar
• Tsan M-F, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol 2004; 76:514-9; PMID:15178705; http://dx.doi.org/10.1189/jlb.0304127
   PubMed Web of Science ®Google Scholar
• Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 2002; 168:5233-9; PMID:11994480; http://dx.doi.org/10.4049/jimmunol.168.10.5233
   PubMed Web of Science ®Google Scholar
• Moghimpour Bijani F, Vallejo JG, Rezaei N. Toll-like receptor signaling pathways in cardiovascular diseases: challenges and opportunities. Int Rev Immunol 2012; 3:379-95; http://dx.doi.org/10.3109/08830185.2012.706761
   Web of Science ®Google Scholar
• Wallin R, Lundqvist A, Moré SH, von Bonin A, Kiessling R, Ljunggren H-G. Heat-shock proteins as activators of the innate immune system. Trends Immunol 2002; 23:130-5; PMID:11864840; http://dx.doi.org/10.1016/S1471-4906(01)02168-8
   PubMed Web of Science ®Google Scholar
• Vabulas RM, Ahmad-Nejad P, da Costa C, Miethke T, Kirschning CJ, Häcker H, Wagner H. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 2001; 276:31332-9; PMID:11402040; http://dx.doi.org/10.1074/jbc.M103217200
   PubMed Web of Science ®Google Scholar
• Dybdahl B, Wahba A, Lien E, Flo TH, Waage A, Qureshi N, Sellevold OF, Espevik T, Sundan A. Inflammatory response after open heart surgery release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation 2002; 105:685-90; PMID:11839622; http://dx.doi.org/10.1161/hc0602.103617
   PubMed Web of Science ®Google Scholar
• Park JS, Svetkauskaite D, He Q, Kim J-Y, Strassheim D, Ishizaka A, Abraham E. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004; 279:7370-7; PMID:14660645; http://dx.doi.org/10.1074/jbc.M306793200
   PubMed Web of Science ®Google Scholar
• Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim J-Y, Strassheim D, Sohn JW, Yamada S, Maruyama I, Banerjee A, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006; 290:C917-C24; PMID:16267105
   PubMed Web of Science ®Google Scholar
• Karikó K, Ni H, Capodici J, Lamphier M, Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 2004; 279:12542-50; http://dx.doi.org/10.1074/jbc.M310175200
   PubMed Web of Science ®Google Scholar
• Watters TM, Kenny EF, O'Neill LA. Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins. Immunol Cell Biol 2007; 85:411-9; PMID:17667936; http://dx.doi.org/10.1038/sj.icb.7100095
   PubMed Web of Science ®Google Scholar
• Belinda LW-C, Wei WX, Hanh BTH, Lei LX, Bow H, Ling DJ. SARM. a novel Toll-like receptor adaptor, is functionally conserved from arthropod to human. Mol Immunol 2008; 45:1732-42; PMID:17980913; http://dx.doi.org/10.1016/j.molimm.2007.09.030
   PubMed Web of Science ®Google Scholar
• Horng T, Barton GM, Flavell RA, Medzhitov R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 2002; 420:329-33; PMID:12447442; http://dx.doi.org/10.1038/nature01180
   PubMed Web of Science ®Google Scholar
• Peng J, Yuan Q, Lin B, Panneerselvam P, Wang X, Luan XL, Lim SK, Leung BP, Ho B, Ding JL. SARM inhibits both TRIF-and MyD88-mediated AP-1 activation. Eur J Immunol 2010; 40:1738-47; PMID:20306472; http://dx.doi.org/10.1002/eji.200940034
   PubMed Web of Science ®Google Scholar
• Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17:1-14; PMID:15585605; http://dx.doi.org/10.1093/intimm/dxh186
   PubMed Web of Science ®Google Scholar
• Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun 2009; 388:621-5; PMID:19686699; http://dx.doi.org/10.1016/j.bbrc.2009.08.062
   PubMed Web of Science ®Google Scholar
• Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3–mediated interferon-β induction. Nat Immunol 2003; 4:161-7; PMID:12539043; http://dx.doi.org/10.1038/ni886
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Sato S, Hemmi H, Uematsu S, Hoshino K, Kaisho T, Takeuchi O, Takeda K, Akira S. TRAM is specifically involved in the Toll-like receptor 4–mediated MyD88-independent signaling pathway. Nat Immunol 2003; 4:1144-50; PMID:14556004; http://dx.doi.org/10.1038/ni986
   PubMed Web of Science ®Google Scholar
• O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007; 7:353-64; PMID:17457343; http://dx.doi.org/10.1038/nri2079
   PubMed Web of Science ®Google Scholar
• Town T, Nikolic V, Tan J. The microglial “activation” continuum: from innate to adaptive responses. J Neuroinflammation 2005; 2:24; http://dx.doi.org/10.1186/1742-2094-2-24
   PubMed Web of Science ®Google Scholar
• Carpentier PA, Duncan DAS, Miller SD. Glial toll-like receptor signaling in central nervous system infection and autoimmunity. Brain Behav Immun 2008; 22:140-7; PMID:17920811
   PubMed Web of Science ®Google Scholar
• Hanke ML, Kielian T. Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential. Clin Sci 2011; 121:367-87; http://dx.doi.org/10.1042/CS20110164
   PubMed Web of Science ®Google Scholar
• Pelvig D, Pakkenberg H, Stark A, Pakkenberg B. Neocortical glial cell numbers in human brains. Neurobiol Aging 2008; 29:1754-62; PMID:17544173; http://dx.doi.org/10.1016/j.neurobiolaging.2007.04.013
   PubMed Web of Science ®Google Scholar
• Olson JK, Miller SD. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 2004; 173:3916-24; PMID:15356140; http://dx.doi.org/10.4049/jimmunol.173.6.3916
   PubMed Web of Science ®Google Scholar
• Babcock AA, Wirenfeldt M, Holm T, Nielsen HH, Dissing-Olesen L, Toft-Hansen H, Millward JM, Landmann R, Rivest S, Finsen B, et al. Toll-like receptor 2 signaling in response to brain injury: an innate bridge to neuroinflammation. J Neurosci 2006; 26:12826-37; PMID:17151286; http://dx.doi.org/10.1523/JNEUROSCI.4937-05.2006
   PubMed Web of Science ®Google Scholar
• Iliev AI, Stringaris AK, Nau R, Neumann H. Neuronal injury mediated via stimulation of microglial toll-like receptor-9 (TLR9). FASEB J 2004; 18:412-4
   PubMedGoogle Scholar
• Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature 2001; 413:732-8; PMID:11607032; http://dx.doi.org/10.1038/35099560
   PubMed Web of Science ®Google Scholar
• Jack CS, Arbour N, Manusow J, Montgrain V, Blain M, McCrea E, Shapiro A, Antel JP. TLR signaling tailors innate immune responses in human microglia and astrocytes. J Immunol 2005; 175:4320-30; PMID:16177072; http://dx.doi.org/10.4049/jimmunol.175.7.4320
   PubMed Web of Science ®Google Scholar
• Farina C, Krumbholz M, Giese T, Hartmann G, Aloisi F, Meinl E. Preferential expression and function of Toll-like receptor 3 in human astrocytes. J Neuroimmunol 2005; 159:12-9; PMID:15652398; http://dx.doi.org/10.1016/j.jneuroim.2004.09.009
   PubMed Web of Science ®Google Scholar
• Farina C, Aloisi F, Meinl E. Astrocytes are active players in cerebral innate immunity. Trends Immunol 2007; 28:138-45; PMID:17276138; http://dx.doi.org/10.1016/j.it.2007.01.005
   PubMed Web of Science ®Google Scholar
• Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002; 61:1013-21; PMID:12430718
   PubMed Web of Science ®Google Scholar
• Kigerl KA, Lai W, Rivest S, Hart RP, Satoskar AR, Popovich PG. Toll-like receptor (TLR)-2 and TLR-4 regulate inflammation, gliosis, and myelin sparing after spinal cord injury. J Neurochem 2007; 102:37-50; PMID:17403033; http://dx.doi.org/10.1111/j.1471-4159.2007.04524.x
   PubMed Web of Science ®Google Scholar
• Tang S-C, Arumugam TV, Xu X, Cheng A, Mughal MR, Jo DG, Lathia JD, Siler DA, Chigurupati S, Ouyang X, et al. Pivotal role for neuronal toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci 2007; 104:13798-803; http://dx.doi.org/10.1073/pnas.0702553104
   PubMed Web of Science ®Google Scholar
• Cameron JS, Alexopoulou L, Sloane JA, DiBernardo AB, Ma Y, Kosaras B, Flavell R, Strittmatter SM, Volpe J, Sidman R, et al. Toll-like receptor 3 is a potent negative regulator of axonal growth in mammals. J Neurosci 2007; 27:13033-41; PMID:18032677; http://dx.doi.org/10.1523/JNEUROSCI.4290-06.2007
   PubMed Web of Science ®Google Scholar
• Maroso M, Balosso S, Ravizza T, Liu J, Bianchi M, Vezzani A. Interleukin-1 type 1 receptor/Toll-like receptor signalling in epilepsy: the importance of IL-1beta and high-mobility group box 1. J Internal Med 2011; 270:319-26; PMID:21793950; http://dx.doi.org/10.1111/j.1365-2796.2011.02431.x
   PubMed Web of Science ®Google Scholar
• Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat Rev Neurol 2011; 7:31-40; PMID:21135885; http://dx.doi.org/10.1038/nrneurol.2010.178
   PubMed Web of Science ®Google Scholar
• Devinsky O, Vezzani A, Najjar S, De Lanerolle NC, Rogawski MA. Glia and epilepsy: excitability and inflammation. Trends Neurosci 2013; 36:174-84; PMID:23298414; http://dx.doi.org/10.1016/j.tins.2012.11.008
   PubMed Web of Science ®Google Scholar
• Peltola J, Hurme M, Miettinen A, Keränen T. Elevated levels of interleukin-6 may occur in cerebrospinal fluid from patients with recent epileptic seizures. Epilepsy Res 1998; 31:129-33; PMID:9714504; http://dx.doi.org/10.1016/S0920-1211(98)00024-2
   PubMed Web of Science ®Google Scholar
• Vezzani A. Inflammation and epilepsy. Epilepsy Curr 2005; 5:1-6; http://dx.doi.org/10.1111/j.1535-7597.2005.05101.x
   PubMedGoogle Scholar
• Aronica E, Crino PB. Inflammation in epilepsy: clinical observations. Epilepsia 2011; 52:26-32; PMID:21542843; http://dx.doi.org/10.1111/j.1528-1167.2011.03033.x
   PubMed Web of Science ®Google Scholar
• Galic MA, Riazi K, Heida JG, Mouihate A, Fournier NM, Spencer SJ, Kalynchuk LE, Teskey GC, Pittman QJ. Postnatal inflammation increases seizure susceptibility in adult rats. J Neurosci 2008; 28:6904-13; PMID:18596165; http://dx.doi.org/10.1523/JNEUROSCI.1901-08.2008
   PubMed Web of Science ®Google Scholar
• Rodgers KM, Hutchinson MR, Northcutt A, Maier SF, Watkins LR, Barth DS. The cortical innate immune response increases local neuronal excitability leading to seizures. Brain 2009; 132:2478-86; PMID:19567702; http://dx.doi.org/10.1093/brain/awp177
   PubMed Web of Science ®Google Scholar
• Maroso M, Balosso S, Ravizza T, Liu J, Aronica E, Iyer AM, Rossetti C, Molteni M, Casalgrandi M, Manfredi AA, et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med 2010; 16:413-9; PMID:20348922; http://dx.doi.org/10.1038/nm.2127
   PubMed Web of Science ®Google Scholar
• Zurolo E, Iyer A, Maroso M, Carbonell C, Anink JJ, Ravizza T, Fluiter K, Spliet WG, van Rijen PC, Vezzani A, et al. Activation of Toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development. Brain 2011; 134:1015-32; PMID:21414994; http://dx.doi.org/10.1093/brain/awr032
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Signaling to NF-κB by Toll-like receptors. Trends Mol Med 2007; 13:460-9; PMID:18029230; http://dx.doi.org/10.1016/j.molmed.2007.09.002
   PubMed Web of Science ®Google Scholar
• Vezzani A. Epilepsy and inflammation in the brain: overview and pathophysiology. Epilepsy Curr 2014; 14:3-7; http://dx.doi.org/10.5698/1535-7511-14.s2.3
   PubMed Web of Science ®Google Scholar
• Galic M, Riazi K, Henderson A, Tsutsui S, Pittman Q. Viral-like brain inflammation during development causes increased seizure susceptibility in adult rats. Neurobiol Dis 2009; 36:343-51; PMID:19660546; http://dx.doi.org/10.1016/j.nbd.2009.07.025
   PubMed Web of Science ®Google Scholar
• Bo T, Chen Y, Mao D, Li Y, Zhu X. [Long-term effects of neonatal recurrent seizures on gamma-aminobutyric acid A receptor alpha1 and gamma2 subunit expressions in the rat brain]. Beijing Da Xue Xue Bao 2006; 38:628-33; PMID:17173085
   PubMedGoogle Scholar
• Zhang G, Raol YSH, Hsu FC, Brooks-Kayal AR. Long-term alterations in glutamate receptor and transporter expression following early-life seizures are associated with increased seizure susceptibility. J Neurochem 2004; 88:91-101; PMID:14675153; http://dx.doi.org/10.1046/j.1471-4159.2003.02124.x
   PubMed Web of Science ®Google Scholar
• Vezzani A, Balosso S, Ravizza T. The role of cytokines in the pathophysiology of epilepsy. Brain Behav Immun 2008; 22:797-803; PMID:18495419; http://dx.doi.org/10.1016/j.bbi.2008.03.009
   PubMed Web of Science ®Google Scholar
• Balosso S, Maroso M, Sanchez-Alavez M, Ravizza T, Frasca A, Bartfai T, Vezzani A. A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1beta. Brain 2008; 131:3256-65; PMID:18952671; http://dx.doi.org/10.1093/brain/awn271
   PubMed Web of Science ®Google Scholar
• Dubé CM, Ravizza T, Hamamura M, Zha Q, Keebaugh A, Fok K, Andres AL, Nalcioglu O, Obenaus A, Vezzani A, Baram TZ. Epileptogenesis provoked by prolonged experimental febrile seizures: mechanisms and biomarkers. J Neurosci 2010; 30:7484-94; http://dx.doi.org/10.1523/JNEUROSCI.0551-10.2010
   PubMed Web of Science ®Google Scholar
• Yuskaitis CJ, Beurel E, Jope RS. Evidence of reactive astrocytes but not peripheral immune system activation in a mouse model of Fragile × syndrome. Biochim Biophys 2010; 1082:1006-12; http://dx.doi.org/10.1016/j.bbadis.2010.06.015
   Web of Science ®Google Scholar
• Lee RH, Mills EA, Schwartz N, Bell MR, Deeg KE, Ruthazer ES, Marsh-Armstrong N, Aizenman CD. Neurodevelopmental effects of chronic exposure to elevated levels of pro-inflammatory cytokines in a developing visual system. Neural Dev 2010; 5:1-18; PMID:20047651; http://dx.doi.org/10.1186/1749-8104-5-2
   PubMed Web of Science ®Google Scholar
• Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005; 57:67-81; PMID:15546155; http://dx.doi.org/10.1002/ana.20315
   PubMed Web of Science ®Google Scholar
• Randle JC, Harding MW, Ku G, Schönharting M, Kurrle R. ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs. Expert Opin Invest Drugs 2001; 10:1207-9; PMID:11772244; http://dx.doi.org/10.1517/13543784.10.7.1207
   PubMed Web of Science ®Google Scholar
• Wannamaker W, Davies R, Namchuk M, Pollard J, Ford P, Ku G, Decker C, Charifson P, Weber P, Germann UA, et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3, 3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R, 3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1β and IL-18. J Pharmacol Exp Ther 2007; 321:509-16; PMID:17289835; http://dx.doi.org/10.1124/jpet.106.111344
   PubMed Web of Science ®Google Scholar
• Ravizza T, Lucas SM, Balosso S, Bernardino L, Ku G, Noé F, Malva J, Randle JC, Allan S, Vezzani A. Inactivation of caspase-1 in rodent brain: a novel anticonvulsive strategy. Epilepsia 2006; 47:1160-8; PMID:16886979; http://dx.doi.org/10.1111/j.1528-1167.2006.00590.x
   PubMed Web of Science ®Google Scholar
• Ravizza T, Noé F, Zardoni D, Vaghi V, Sifringer M, Vezzani A. Interleukin converting enzyme inhibition impairs kindling epileptogenesis in rats by blocking astrocytic IL-1β production. Neurobiol Dis 2008; 31:327-33; PMID:18632279; http://dx.doi.org/10.1016/j.nbd.2008.05.007
   PubMed Web of Science ®Google Scholar
• Incorporated VP. Study of VX-765 in subjects with treatment-resistant partial epilepsy. (Study code-clinicaltrials.gov identifier: NCT01048255)
   Google Scholar
• Yang QW, Wang J-Z, Li J-C, Zhou Y, Zhong Q, Lu F-L, Xiang J. High-mobility group protein box-1 and its relevance to cerebral ischemia. J Cereb Blood Flow Metab 2009; 30:243-54; PMID:9794402
   PubMed Web of Science ®Google Scholar
• Barnes GN. “For whom the bell tolls”: blockade of toll-like receptors may regulate seizure occurrence. Epilepsy Curr 2010; 10:164-5; PMID:21157547; http://dx.doi.org/10.1111/j.1535-7511.2010.01389.x
   PubMed Web of Science ®Google Scholar
• Walker L, Sills GJ. Inflammation and epilepsy: the foundations for a new therapeutic approach in epilepsy? Epilepsy Curr 2012; 12:8-12; http://dx.doi.org/10.5698/1535-7511-12.1.8
   PubMed Web of Science ®Google Scholar
• Frémont L. Biological effects of resveratrol. Life Sci 2000; 66:663-73; http://dx.doi.org/10.1016/S0024-3205(99)00410-5
   PubMed Web of Science ®Google Scholar
• Bhat KP, Kosmeder JW, Pezzuto JM. Biological effects of resveratrol. Antioxid Redox Signal 2001; 3:1041-64; PMID:11813979; http://dx.doi.org/10.1089/152308601317203567
   PubMed Web of Science ®Google Scholar
• Clément M-V, Hirpara JL, Chawdhury S-H, Pervaiz S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 1998; 92:996-1002
   PubMed Web of Science ®Google Scholar
• Albani D, Polito L, Signorini A, Forloni G. Neuroprotective properties of resveratrol in different neurodegenerative disorders. Biofactors 2010; 36:370-6; PMID:20848560; http://dx.doi.org/10.1002/biof.118
   PubMed Web of Science ®Google Scholar
• Youn HS, Lee JY, Fitzgerald KA, Young HA, Akira S, Hwang DH. Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. J Immunol 2005; 175:3339-46; PMID:16116226; http://dx.doi.org/10.4049/jimmunol.175.5.3339
   PubMed Web of Science ®Google Scholar
• Wu Z, Xu Q, Zhang L, Kong D, Ma R, Wang L. Protective effect of resveratrol against kainate-induced temporal lobe epilepsy in rats. Neurochem Res 2009; 34:1393-400; PMID:19219549; http://dx.doi.org/10.1007/s11064-009-9920-0
   PubMed Web of Science ®Google Scholar
• Gupta Y, Briyal S, Chaudhary G. Protective effect of tans-resveratrol against kainic acid-induced seizures and oxidative stress in rats. Pharmacol Biochem Behav 2002; 71:245-9; http://dx.doi.org/10.1016/S0091-3057(01)00663-3
   PubMed Web of Science ®Google Scholar
• Zhang F, Liu J, Shi J-S. Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation. Eur J Pharmacol 2010; 636:1-7; PMID:20361959; http://dx.doi.org/10.1016/j.ejphar.2010.03.043
   PubMed Web of Science ®Google Scholar
• Falchetti R, Fuggetta MP, Lanzilli G, Tricarico M, Ravagnan G. Effects of resveratrol on human immune cell function. Life Sci 2001; 70:81-96; PMID:11764009; http://dx.doi.org/10.1016/S0024-3205(01)01367-4
   PubMed Web of Science ®Google Scholar
• Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, Jang M, Pezzuto JM, Dannenberg AJ. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 1998; 273:21875-82; PMID:9705326; http://dx.doi.org/10.1074/jbc.273.34.21875
   PubMed Web of Science ®Google Scholar